Literature DB >> 9359732

Targeted suppression of cytokine production in monocytes but not in T lymphocytes by a tetravalent guanylhydrazone (CNI-1493).

L Björk1, K J Tracey, P Ulrich, M Bianchi, P S Cohen, K Akerlund, T E Fehniger, U Andersson, J Andersson.   

Abstract

Image analysis was used to study the cytokine-inhibitory effect of the nitric oxide inhibitor tetravalent guanylhydrazone (CNI-1493) in individual immunocytochemically stained human peripheral blood mononuclear cells (PBMC). CNI-1493 inhibited lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-alpha, interleukin (IL)-1alpha, IL-1beta, IL-6, and IL-8 production whether or not LPS stimulation was enhanced by interferon (IFN)-gamma priming. Addition of TNF-alpha to CNI-1493-exposed LPS-stimulated cells partially restored the incidence of IL-1alpha-, IL-1beta-, and IL-8-producing cells. TNF-alpha production induced by costimulation by ligation of CD3 and CD28 was inhibited by CNI-1493 in monocytes but not in T lymphocytes. The prevalence of IL-2-, IFN-gamma-, and TNF-beta-producing T cells was not reduced by CNI-1493. Phorbol ester and ionomycin activation also resulted in a CNI-1493 -induced inhibition of TNF-alpha in monocytes but resistant production of TNF-alpha, IL-2, and IFN-gamma by T cells. Thus, CNI-1493 preferentially inhibited synthesis of proinflammatory cytokines in monocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359732     DOI: 10.1086/514126

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats.

Authors:  K kerlund; H Erlandsson Harris; K J Tracey; H Wang; T Fehniger; L Klareskog; J Andersson; U Andersson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis : a therapeutic study using a macrophage-deactivating compound.

Authors:  K Palmblad; H Erlandsson-Harris; K J Tracey; U Andersson
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 3.  Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.

Authors:  Namrita Halder; Girdhari Lal
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

4.  Suppression of macrophage activation with CNI-1493 increases survival in infant rats with systemic Haemophilus influenzae infection.

Authors:  C Granert; H Abdalla; L Lindquist; A Diab; M Bahkiet; K J Tracey; J Andersson
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm.

Authors:  George Bowman; Robert H Bonneau; Vernon M Chinchilli; Kevin J Tracey; Kevin M Cockroft
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

6.  The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation.

Authors:  Anthony J Hesketh; Caroline Maloney; Christopher A Behr; Morris C Edelman; Richard D Glick; Yousef Al-Abed; Marc Symons; Samuel Z Soffer; Bettie M Steinberg
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

7.  Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia.

Authors:  Ian S Miller; Sebastien Didier; David W Murray; Tia H Turner; Magimairajan Issaivanan; Rosamaria Ruggieri; Yousef Al-Abed; Marc Symons
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.